Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.93 USD | -6.39% | +23.61% | -26.01% |
05-02 | CUREVAC : A missed opportunity | |
04-26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.01% | 701M | |
+21.76% | 47.9B | |
+46.62% | 41.42B | |
-2.18% | 40.7B | |
-6.20% | 28.92B | |
+10.19% | 25.55B | |
-20.87% | 19.27B | |
-0.32% | 12.15B | |
+31.04% | 12.14B | |
-0.47% | 11.99B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac N : Preclinical Data Shows Sharp Reduction of Liver Fibrosis With mRNA Therapeutic; Shares Down Midday